Novo and Viatris settle Ozempic patent suit as generic entry date remains unknown

Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster diabetes drug Ozempic.

The Danish company declined to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA grants breakthrough status for J&J’s nipocalimab for HDFN

Share this article Nipocalimab is the only therapy in the clinics for haemolytic disease of the foetus and newborn. Credit: Iryna Inshyna / Shutterstock.com. The

February 12, 2024

AbbVie’s new AI deal; Roche’s PhIII win in breast cancer; SpringWorks to raise $275M

Plus, news about Eligo Bioscience, EyePoint, Xenon and Merus: AbbVie signs AI pact: For $30 million upfront, the pharma is partnering with BigHat Biosciences to

December 6, 2023

Affimed’s early lung cancer data disappoint; Indapta’s $22M round

Plus, news about Akamis Bio, Tenaya Therapeutics, Reviva, Actuate Therapeutics, CG Oncology and Candel Therapeutics: Affimed shares early lung cancer data: In a Phase 1

December 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.